PLSE · Pulse Biosciences, Inc.
$50.50
+2.60 (+5.43%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$3.68B
Shares
71.32M
Volume · Oct 5
433.5K
Avg daily vol (3M)
497.63K
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$47.90
Open$50.13
Day$47.75–50.71
52W close$12.66–55.20
Avg vol 30d614K
Short int3.1M · 4.4% float · 3.9d
Short vol54%
Last earningsAug 6, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Nov 2, 2026
Est · unconfirmed
· in 4 wks
filed Aug 6, 2026
call held Aug 6, 2026
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+152.2%
Trailing year
Short interest
4.4%
Latest settlement · 3.9 days to cover
AI Brief
Q2 FY26 earnings call · Aug 6, 2026
Q2 FY26
TL;DR. Pulse Biosciences reported accelerated NANOPULSE-AF pivotal IDE enrollment, surpassing the halfway point with a confirmed early Q4 completion target even after expanding enrollment to 164 patients, while strengthening the balance sheet to $101.6 million via a $57.5 million ATM raise, though quarterly net loss widened to $24.7 million on $0.4 million in product revenue.
Bullish
- + NANOPULSE-AF pivotal IDE enrollment surpassed the halfway point with over 82 evaluable patients, and the company reiterated an early Q4 completion target even after expanding enrollment to 164 patients.
- + Strong EU feasibility data showed 100% freedom from AF at 6 months and 96% at 12 months with a 1.7% serious adverse event rate, supporting a CE Mark submission for the catheter in the second half of 2026.
- + Surgical clamp EU feasibility showed 94% pulmonary vein isolation success at 3 months, with CE Mark filing for the nPulse Cardiac Surgical System on schedule before the end of 2026.
Bearish
- − GAAP net loss widened to $24.7 million from $19.2 million in the prior year period, with quarterly operating cash use of $18.7 million.
- − Product revenue remained minimal at $434,000 in Q2 2026 with the company still in a 'disciplined launch focused on clinical and market development.'
- − GAAP costs and expenses increased $5.4 million year-over-year to $25.7 million, and the company guided quarterly non-GAAP operating expenses to 'remain in this range' going forward.
- − Total non-GAAP net loss widened to $19.4 million from $13.7 million in the prior year period.
From the call
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceOverall
Neutral
SellHoldBuy
Technical
Neutral
Momentum
Strong
Sentiment
Bullish
Fundamentals
Limited
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.59
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
+73%
above
Price vs 50-day avg
+2%
above
RSI (14)
44
neutral
MACD trend
Negative
52-week position
83%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−12%
trailing
6-month return
+153%
trailing
YTD return
+249%
this year
Relative strength
+141%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $47 › 200d $28 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +21 funds added
Insider flow
Accumulating
Net +$199.9K over 90 days · 0% sells
Short interest
Rising
4.40% of float · ▲ +0.6% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
106 holders — near 3-yr high, broad support
Squeeze score
63
elevated · 0–100
Fundamentals
Not enough data for a confident read.
Quant / Vol
risk profile
Volatility
88%
annualized · 1-yr
Max drawdown
−37%
past year
ATR
7.2%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Neutral
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
+73%
Bullish
Price vs 50-day avg
+2%
Bullish
RSI (14)
44
Neutral
MACD trend
Negative
Bearish
52-week position
83%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross)
No cross
50d $47 › 200d $28 — 50d above 200d
Institutional flow
Accumulating
+10% holders QoQ · +21 funds added
Insider flow
Accumulating
Net +$199.9K over 90 days · 0% sells
Short interest
Rising
4.40% of float · ▲ +0.6% MoM · 3.9 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
106 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $13
Now $48 · 83%
Range high $55
vs 200-day avg +73%
vs 50-day avg +2%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| active investigational sites | 12 | Q2 2026 | — |
| Cash used in operating activities | $18.7M | Q2 2026 | — |
| evaluable patients enrolled in NANOPULSE-AF | 82 | Q2 2026 | — |
| net proceeds raised under ATM program | $46.8M | Q2 2026 | — |
| Non-GAAP costs and expenses non-GAAP | $20.5M | Q2 2026 | — |
| Non-GAAP net loss non-GAAP | -$19.4M | Q2 2026 | — |
GAAP → non-GAAP reconciliationGAAP GAAP Net loss -24.66M
+4.97M Stock-based compensation expense
+255K Depreciation and amortization
+0K Legal settlement
= Non-GAAP Net loss -19.43M
|
|||
| PRECISE-BTN study expansion to patient count | 100 | Q2 2026 | — |
| PTMC feasibility study designed enrollment | 30 | Q2 2026 | — |
| total evaluable patient target for NANOPULSE-AF | 164 | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Medical Instruments & Supplies — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
PLSE
this stock
Pulse Biosciences, Inc.
|
$3.68B | +248.9% | — | — | 4.4% |
|
ISRG
Intuitive Surgical Inc
|
$143.14B | -30.8% | +20.5% | 46.5 | 2.3% |
|
BDX
Becton Dickinson & Co
|
$49.57B | — | +8.2% | — | 4.2% |
|
MDLN
Medline Inc.
|
$45.62B | -15.2% | +11.5% | — | 3.1% |
|
RMD
Resmed Inc
|
$32.02B | -9.1% | +13.4% | 21.3 | 9.8% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Smart Money
Financials
Filings
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| PLSE | -7.2% | -12.5% | +153.2% | -4.1% | +248.9% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | -7.0% | -12.0% | +141.0% | -5.0% | +236.0% |